RT Journal Article
SR Electronic
T1 Parenteral Formulation of Flavopiridol (NSC-649890)
JF PDA Journal of Pharmaceutical Science and Technology
JO PDA J Pharm Sci Technol
FD Parenteral Drug Association (PDA)
SP 356
OP 359
VO 50
IS 6
A1 Dannenfelser, Rose-Marie
A1 Surakitbanharn, Yosyong
A1 Tabibi, S. Esmail
A1 Yalkowsky, Samuel H.
YR 1996
UL http://journal.pda.org/content/50/6/356.abstract
AB Flavopiridol [5,7-dihydroxy-8-(4-N-methyl-2-hydroxypyridyl)-6′-chloroflavone hydrochloride] is a flavonoid with weak electrolyte properties and an intrinsic aqueous solubility of 0.024 mg/mL. Neither cosolvency, complexation, nor pH control alone can produce an acceptable 10 mg/mL formulation that will not precipitate when diluted with blood. However, a combination of buffer and cyclodextrin or buffer and cosolvent can produce an acceptable 10 mg/mL formulation. In this paper, Flavopiridol is shown to be stable for at least one year in 30% hydroxypropyl ß-cyclodextrin/0.1 M citrate buffer (4.52). This formulation does not precipitate for at least one hour upon dilution with Sorensen's phosphate buffer pH 7.4.